The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer - A phase I trial

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3435-3441

  Schwarzlose Schwarck, Sandra ^a   Scholz, Christian W ^a   Regierer, Anne C ^a   Martus, Peter ^b   Neumann, Christian ^a   Habbel, Piet ^a   Liu, Hongyu ^a   Zang, Chuanbing ^a   Schefe, Jan Hendrik ^a   Schulz, Carsten Oliver ^a   Possinger, Kurt ^a   Eucker, Jan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Carboplatin; Everolimus; Metastatic breast cancer; Phase I; RAD001

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; EVEROLIMUS; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFECTION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; STOMACH PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84865697746     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, Le QT, Markman M, Masters GA, Newman L, Obel JC, Seidman AD, Smith SM, Vogelzang N and Petrelli NJ: Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 28: 5327-5347, 2010.
2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2012. Ann Oncol 23: 1044-105, 2012.
3. Van den Hurk CJG, Eckel R, van de Poll-Franse LV, Coebergh JW, Nortier JW, Hölzel D, Breed WP and Engel J: Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population based analysis of the Munich Cancer Registry. Breast Cancer Res Treat 128: 795-805, 2011.
4. Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'reilly SE and Olivotto IA: The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110: 973-979, 2007.
5. Bernard-Marty C, Cardoso F and Piccart MJ: Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9: 617-732, 2004.
6. Valero V and Hortobagyi GN: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 21: 959-962, 2003.
7. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM and Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364: 205-214, 2011.
8. Chan D, Yeo WL, Tiemsim Cordero M, Wong CI, Chuah B, Soo R, Tan SH, Lim SE, Goh BC and Lee SC: Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Invest New Drugs 28: 859-865, 2010.
9. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L and Slamon D: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786-2792, 2006.
10. Decatris MP, Sundar S and O'Byrne KJ: Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat Rev 4: 53-81, 2004.
11. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A and Crown J; Breast Cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283, 2011.
12. O'Brien ME, Talbot DC and Smith IE: Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11: 2112-2117, 1993.
13. Meric-Bernstam F and Gonzalez-Angulo A: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287, 2009.
14. Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000.
15. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC and Testa JR: RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67: 2408-2413, 2007.
16. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB and Meric-Bernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10: 7031-7042, 2004.
17. Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E and Faivre S: Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines Cancer. Chemother Pharmacol 62: 305-313, 2008.
18. Campone M, Levy V, Bourbouloux E, Berton Rigaud D, Bootle D, Dutreix C, Zoellner U, Shand N, Calvo F and Raymond E: Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 100: 315-321, 2009.
19. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D and Öberg K: RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523, 2011.
20. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L and Coiffier B: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822-3829, 2009.
21. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin TA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D and Ravaud A; RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
22. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L and Motzer RJ; Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
23. Liu H, Zang C, Schefe J, Schwarzlose-Schwarck S, Regierer A, Elstner E, Schulz C, Scholz C, Possinger K and Eucker J: The mTor inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Anticancer Res 31: 2713-2723, 2011.
24. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA and Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120: 747-759, 2005.
25. Ellard S, Clemons M, Gelmon K, Norris B, Kennecke H., Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei M, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L and Seymour L: Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27: 4536-4541, 2009.
26. Tanaka C, O'Reilly T, Kovarik J, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G and Lane HA: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 28: 1596-1602, 2008.
27. O'Donnell A, Faivre S, Burris III H, Rea D, Papadimitrakopoulou V, Shand N, Lane H, Hazell K, Zoellner U, Kovarik J, Brock C, Jones S, Raymond E and Judson I: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588-1585, 2008.
28. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE and Eisenhauer EA: Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 29: 3278-3285, 2011.
29. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria J, Naughton M and Hurvitz S: Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28: 5110-5115, 2010.
30. Fury MG, Sherman E, Haque S, Korte S, Lisa D, Shen R, Wu N and Pfister D: A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother Pharmacol 69: 591-598, 2012.
31. Ghobrial I, Gertz M, LaPlant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell S, DeAngelo D, Dispenzieri D, Bergsagel L, Reeder C, Anderson K, Richardson P, Treon S and Witzig T: Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia. J Clin Oncol 28: 1408-1414, 2009.
32. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D and Esteva FJ: Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29: 3126-3132, 2011
33. Garcia-Morales P, Hernando E, Carrasco-Garcia E, Menendez-Gutierrez MP, Saceda M and Martinez-Lacaci I: Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol Cancer Ther 5: 2172-2181, 2006.